by Symmetron | Jan 21, 2019
juvenile idiopathic arthritis Tocilizumab in polyarticular juvenile idiopathic arthritis: a cost-utility model for the United Kingdom Value in Health. 2013;16(7):A564 Authors Chang S, Sawyer L, Dejonckheere F, van Suijlekom-Smit LW, Anink J, Diamantopoulos A Process...
by Symmetron | Jan 21, 2019
juvenile idiopathic arthritis Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland Annals of the Rheumatic Diseases. 2013;71:258-259 Authors Hallinen T, Soini EJ, Diamantopoulos A, Dejonckheere F, Vihervaara V, Hautala A,...
by Symmetron | Jan 21, 2019
Hypertension Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation Health Technology Assessment....
by Symmetron | Jan 21, 2019
Hepatitis Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom Value in Health. 2015;18(6):800-9 Authors Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E,...
by Symmetron | Jan 21, 2019
Peripheral arterial disease Cost-effectiveness of supervised exercise for the treatment of intermittent claudication European Journal of Vascular and Endovascular Surgery. 2013;46(6):707-14 Authors Bermingham SL, Sparrow K, Mullis R, Fox M, Shearman C, Bradbury A,...
Recent Comments